Adaptive stimulation improves motor control
- Trial ID
- NCT07216976
- Official Title
- Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study
- Goal
- Adaptive stimulation improves motor control
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- MedtronicNeuro
- Study Type
- INTERVENTIONAL
- Enrollment
- 62 participants
- Conditions
- Parkinson's Disease
- Interventions
- Percept™ PC and Percept RC with Adaptive DBS (aDBS™)
Plain-Language Summary
The goal is to make deep brain stimulation more personalized so motor symptoms are better controlled with fewer side effects, by using the brain's own signals to guide when and how much stimulation is delivered. It uses Medtronic's Percept PC with an adaptive DBS algorithm that senses alpha‑beta local field potentials (8 to 30 Hz) from STN or GPi leads and automatically raises or lowers stimulation in real time, working alongside your current Parkinson medications and clinician settings rather than replacing them. Looking for adults 18 and older who already have a Percept PC and compatible bilateral STN or GPi leads, who respond to DBS and have stable medications and stimulation, and who show detectable alpha‑beta signals on screening; people with major depression, incompatible or extra implanted devices, low INS battery life, pregnancy or breastfeeding, or inability to use the patient programmer are excluded.
Locations
- Xuanwu Hospital, Beijing, Beijing Municipality, China
- Sun Yat-sen Hospital, Guangzhou, Guangdong, China
- Huashan Hospital, Shanghai, Shanghai Municipality, China
- Ruijin Hospital, Shanghai, Shanghai Municipality, China
- West China Hospital, Chengdu, Sichuan, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Percept™ PC and Percept RC with Adaptive DBS (aDBS™). The goal is to make deep brain stimulation more personalized so motor symptoms are better controlled with fewer side effects, by using the brain's own signals to guide when and how much stimulation is delivered. It uses Medtronic's Percept PC with an adaptive DBS algorithm that senses alpha‑beta local field potentials (8 to 30 Hz) from STN or GPi leads and automatically raises or lowers stimulation in real time, working alongside your current Parkinson medications and clinician settings rather than replacing them. Looking for adults 18 and older who already have a Percept PC and compatible bilateral STN or GPi leads, who respond to DBS and have stable medications and stimulation, and who show detectable alpha‑beta signals on screening; people with major depression, incompatible or extra implanted devices, low INS battery life, pregnancy or breastfeeding, or inability to use the patient programmer are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 5 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 1 month.